CAI

$18.54

Post-MarketAs of Mar 17, 8:00 PM UTC

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$18.54
Potential Upside
5%
Whystock Fair Value$19.47
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and a...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.24B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-45.37%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
7.16

Recent News

Simply Wall St.
Mar 17, 2026

Caris Life Sciences (CAI) Valuation Check After Recent Share Price Rebound

Caris Life Sciences: Event Driven Snapshot Caris Life Sciences (CAI) has drawn investor attention after recent trading, with the stock closing at $19.05 and showing mixed performance over the past week, month and past 3 months. See our latest analysis for Caris Life Sciences. The recent 1 day share price return of 4.96% comes after a weaker stretch, with the 30 day and year to date share price returns of 7.61% and 29.39% declines indicating momentum has been fading rather than building. If...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MT Newswires
Mar 16, 2026

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.8% and the State

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 3, 2026

BTSG vs. CAI: Which Stock Is the Better Value Option?

BTSG vs. CAI: Which Stock Is the Better Value Option?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 1, 2026

Assessing Caris Life Sciences (CAI) Valuation After Recent Share Price Weakness

Caris Life Sciences (CAI) has drawn fresh attention after recent trading left the stock with a one-month return of about a 13% decline and a three-month return near a 23% decline. See our latest analysis for Caris Life Sciences. Those recent share price returns, including a 4.68% 1 day gain and 3.12% 7 day gain against deeper 30 day and year to date share price declines, suggest short term momentum is improving after a weaker stretch. If you are watching how AI driven health companies are...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Mar 1, 2026

Caris Life Sciences Inc (CAI) Q4 2025 Earnings Call Highlights: Record Revenue Surge and ...

Caris Life Sciences Inc (CAI) reports a 125% revenue increase, positive net income, and ambitious 2026 growth targets, driven by molecular profiling success and upcoming innovations.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.